Breast Cancer, Non-metastatic   

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

If so, what dose-fractionation do you utilize? What other factors do you take into consideration?